ReviewPLoS pathogens2025
Re-emergence of chikungunya virus in China by 2025: What we know and what to do?
Review in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of recombinase polymerase amplification-based assays for mosquito-borne virus detection in clinical samples: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2026Pooled it
- Autoantibodies neutralizing type I interferons underlie a third of cases of Chikungunya virus encephalitis or myelitis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Retinoic acid is a translation inhibitor against chikungunya virus both in vitro and invivo.Virologica Sinica · 2026Article
- Research advances in chikungunya virus: Epidemiology, pathogenesis, and control.One health (Amsterdam, Netherlands) · 2026Review
- Pathogenesis of Chronic Arthritis Due to Chikungunya Virus and Advances in Vaccine Development.Viruses · 2026Review
- A brief review of chikungunya fever: From molecular virology to countermeasures.Infectious medicine · 2026Review
- Beyond Chikungunya: Hidden risks of anti-mosquito chemicals.Eco-Environment & Health · 2026Article
- AI-driven drug reposition for pathogens: a new paradigm in pandemic preparedness.Frontiers in chemistry · 2026Review
- Analysis of imported Chikungunya cases in China from 2006 to 2026.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In July 2025, China witnessed its most significant chikungunya virus (CHIKV) outbreak since 2010. As of August 1, with over 6,000 cases reported in Foshan city, Guangdong Province. Although the clinical manifestations have been relatively mild, the rapid transmission within communities warrants our attention. In this context, we emphasize our current knowledge and the necessary actions to take. Specifically, we identify critical gaps in CHIKV control efforts and assess the effectiveness of current measures. These include vector management strategies, viral genomic surveillance, the deployment of newly approved vaccines, and the development of antiviral agents. Overall, to effectively control the epidemic of CHIKV, we require a comprehensive and multifaceted strategy for its prevention and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.